Osteoglycin and Bone-a Systematic Review

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2019 Aug 10

PMID 31396918

Citations 10

Authors

Jakob Starup-Linde

Rikke Viggers

Aase Handberg

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Bone turnover is a regulated process. Osteoglycin is suggested to have an important impact on bone function but may also affect cardiovascular and metabolic functions. This review investigates the action of osteoglycin in bone as well as its potential endocrine effects.

Recent Findings: Osteoglycin is expressed by several tissues including bone and muscle. Some studies suggest that osteoglycin increases osteoblast differentiation whereas others suggest that osteoglycin decreases osteoblast differentiation. Thus, findings on the influence of osteoglycin in bone are conflicting. A recent study found increased bone mass in osteoglycin deficient mice. Another study reported that osteoglycin is a marker of low bone mineral density and vertebral fractures in women with type 2 diabetes. Furthermore, clinical studies link osteoglycin to insulin resistance and cardiovascular disease. Osteoglycin may be a novel marker of a muscle, pancreatic, and bone axis. However, current evidence is limited and further research investigating osteoglycin in both a pre-clinical and a clinical setting is needed.

Citing Articles

Proteomic Analysis of Human Serum Proteins Adsorbed onto Collagen Barrier Membranes.

Shanbhag S, Al-Sharabi N, Fritz-Wallace K, Kristoffersen E, Bunaes D, Romandini M J Funct Biomater. 2024; 15(10).

PMID: 39452600 PMC: 11508515. DOI: 10.3390/jfb15100302.

Proteomic insights into extracellular vesicles in ALS for therapeutic potential of Ropinirole and biomarker discovery.

Kato C, Ueda K, Morimoto S, Takahashi S, Nakamura S, Ozawa F Inflamm Regen. 2024; 44(1):32.

PMID: 38997748 PMC: 11241965. DOI: 10.1186/s41232-024-00346-1.

Association between bone turnover markers, bone mineral density, and serum osteoglycine in middle-aged men with Type 2 Diabetes mellitus.

Mostafa S, Elebrashy I, Haddad H, Shaker O, Razek N, Fayed A Diabetol Metab Syndr. 2024; 16(1):155.

PMID: 38982537 PMC: 11232153. DOI: 10.1186/s13098-024-01388-8.

miRNA-seq analysis of high glucose induced osteoblasts provides insight into the mechanism underlying diabetic osteoporosis.

Zhang Y, Li M, Lou P, Zhang M, Shou D, Tong P Sci Rep. 2024; 14(1):13441.

PMID: 38862780 PMC: 11166950. DOI: 10.1038/s41598-024-64391-z.

Bone metabolism in diabetes: a clinician's guide to understanding the bone-glucose interplay.

Sheu A, White C, Center J Diabetologia. 2024; 67(8):1493-1506.

PMID: 38761257 PMC: 11343884. DOI: 10.1007/s00125-024-06172-x.

References

Manolagas S, Almeida M . Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol. 2007; 21(11):2605-14. DOI: 10.1210/me.2007-0259. View

Starup-Linde J, Vestergaard P . Biochemical bone turnover markers in diabetes mellitus - A systematic review. Bone. 2015; 82:69-78. DOI: 10.1016/j.bone.2015.02.019. View

Westberg-Rasmussen S, Starup-Linde J, Hermansen K, Holst J, Hartmann B, Vestergaard P . Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone. 2017; 97:261-266. DOI: 10.1016/j.bone.2017.01.027. View

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Delmas P . What do we know about biochemical bone markers?. Baillieres Clin Obstet Gynaecol. 1991; 5(4):817-30. DOI: 10.1016/s0950-3552(05)80289-5. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

Madisen L, Neubauer M, Plowman G, Rosen D, Segarini P, Dasch J . Molecular cloning of a novel bone-forming compound: osteoinductive factor. DNA Cell Biol. 1990; 9(5):303-9. DOI: 10.1089/dna.1990.9.303. View

Ge G, Seo N, Liang X, Hopkins D, Hook M, Greenspan D . Bone morphogenetic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. J Biol Chem. 2004; 279(40):41626-33. DOI: 10.1074/jbc.M406630200. View

Baek S, Cha R, Kang S, Park C, Cha D, Kim S . Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. Tohoku J Exp Med. 2017; 242(4):281-290. DOI: 10.1620/tjem.242.281. View

10.

Petretto E, Sarwar R, Grieve I, Lu H, Kumaran M, Muckett P . Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet. 2008; 40(5):546-52. PMC: 2742198. DOI: 10.1038/ng.134. View

11.

Shanahan C, Cary N, Osbourn J, Weissberg P . Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 1997; 17(11):2437-47. DOI: 10.1161/01.atv.17.11.2437. View

12.

Hygum K, Starup-Linde J, Harslof T, Vestergaard P, Langdahl B . MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol. 2017; 176(3):R137-R157. DOI: 10.1530/EJE-16-0652. View

13.

Khosla S . Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001; 142(12):5050-5. DOI: 10.1210/endo.142.12.8536. View

14.

Chen X, Chen J, Xu D, Zhao S, Song H, Peng Y . Effects of Osteoglycin (OGN) on treating senile osteoporosis by regulating MSCs. BMC Musculoskelet Disord. 2017; 18(1):423. PMC: 5658998. DOI: 10.1186/s12891-017-1779-7. View

15.

Tanaka K, Matsumoto E, Higashimaki Y, Katagiri T, Sugimoto T, Seino S . Role of osteoglycin in the linkage between muscle and bone. J Biol Chem. 2012; 287(15):11616-28. PMC: 3320911. DOI: 10.1074/jbc.M111.292193. View

16.

Bendix E, Johansen E, Ringgaard T, Wolder M, Starup-Linde J . Diabetes and Abdominal Aortic Calcification-a Systematic Review. Curr Osteoporos Rep. 2018; 16(1):42-57. DOI: 10.1007/s11914-018-0418-z. View

17.

Dasch J, Pace D, Avis P, BENTZ H, Chu S . Characterization of monoclonal antibodies recognizing bovine bone osteoglycin. Connect Tissue Res. 1993; 30(1):11-21. DOI: 10.3109/03008209309032927. View

18.

Iozzo R . The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem. 1999; 274(27):18843-6. DOI: 10.1074/jbc.274.27.18843. View

19.

Galluzzi F, Stagi S, Salti R, Toni S, Piscitelli E, Simonini G . Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol. 2005; 153(6):879-85. DOI: 10.1530/eje.1.02052. View

20.

Fuglsang-Nielsen R, Starup-Linde J, Gregersen S, Vestergaard P . The effect of meals on bone turnover - a systematic review with focus on diabetic bone disease. Expert Rev Endocrinol Metab. 2018; 13(5):233-249. DOI: 10.1080/17446651.2018.1518131. View